skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: Single Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

Ribas, Antoni ; Lawrence, Donald ; Atkinson, Victoria ; Agarwal, Sachin ; Miller, Jr, Wilson H ; Carlino, Matteo S ; Fisher, Rosalie ; Long, Georgina V ; Hodi, F Stephen ; Tsoi, Jennifer ; Grasso, Catherine S ; Mookerjee, Bijoyesh ; Zhao, Qing ; Ghori, Razi ; Moreno, Blanca Homet ; Ibrahim, Nageatte ; Hamid, Omid

Nature medicine, 2019-06, Vol.25 (6), p.936-940 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por
2
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, Paolo Antonio ; Ferrucci, Pier Francesco ; Fisher, Rosalie ; Del Vecchio, Michele ; Atkinson, Victoria ; Schmidt, Henrik ; Schachter, Jacob ; Queirolo, Paola ; Long, Georgina V ; Di Giacomo, Anna Maria ; Svane, Inge Marie ; Lotem, Michal ; Bar-Sela, Gil ; Couture, Felix ; Mookerjee, Bijoyesh ; Ghori, Razi ; Ibrahim, Nageatte ; Moreno, Blanca Homet ; Ribas, Antoni

Nature medicine, 2019-06, Vol.25 (6), p.941-946 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por
3
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Marabelle, Aurelien ; Le, Dung T ; Ascierto, Paolo A ; Di Giacomo, Anna Maria ; De Jesus-Acosta, Ana ; Delord, Jean-Pierre ; Geva, Ravit ; Gottfried, Maya ; Penel, Nicolas ; Hansen, Aaron R ; Piha-Paul, Sarina A ; Doi, Toshihiko ; Gao, Bo ; Chung, Hyun Cheol ; Lopez-Martin, Jose ; Bang, Yung-Jue ; Frommer, Ronnie Shapira ; Shah, Manisha ; Ghori, Razi ; Joe, Andrew K ; Pruitt, Scott K ; Diaz, Jr, Luis A

Journal of clinical oncology, 2020-01, Vol.38 (1), p.1-10 [Periódico revisado por pares]

United States: American Society of Clinical Oncology

Texto completo disponível

Citações Citado por
4
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study

Chung, Hyun Cheol ; Saada‐Bouzid, Esma ; Longo, Federico ; Yanez, Eduardo ; Im, Seock‐Ah ; Castanon, Eduardo ; Desautels, Danielle N. ; Graham, Donna M. ; Garcia‐Corbacho, Javier ; Lopez, Juanita ; Dutcus, Corina ; Okpara, Chinyere E. ; Ghori, Razi ; Jin, Fan ; Groisberg, Roman ; Korakis, Iphigenie

Cancer, 2024-06 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Woyach, Jennifer A. ; Flinn, Ian W. ; Awan, Farrukh T. ; Eradat, Herbert ; Brander, Danielle ; Tees, Michael ; Parikh, Sameer A. ; Phillips, Tycel J. ; Ghori, Razi ; Reddy, Nishitha M. ; Farooqui, Mohammed Z.H. ; Byrd, John C. ; Stephens, Deborah M.

Blood, 2022-11, Vol.140 (Supplement 1), p.7004-7006 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50
Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract CT283: Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50

Frost, Nikolaj ; Ghori, Razi ; Roy, Ananya ; Nunes, Ana Tablante ; Yang, James Chih-Hsin

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT283-CT283 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study

Chung, Hyun Cheol ; Saada-Bouzid, Esma ; Muñoz, Federico Longo ; Yanez, Eduardo ; Im, Seock-Ah ; Castanon, Eduardo ; Graham, Donna M. ; Garcia-Corbacho, Javier ; Lopez, Juanita ; Ghori, Razi ; Dutcus, Corina ; Smith, Alan ; Norwood, Kevin ; Gomez-Roca, Carlos

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-07-PS12-07 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort

Gomez-Roca, Carlos ; Yanez, Eduardo ; Im, Seock-Ah ; Castanon Alvarez, Eduardo ; Senellart, Helene ; Doherty, Mark ; García-Corbacho, Javier ; Lopez, Juanita Suzanne ; Basu, Bristi ; Maurice-Dror, Corinne ; Gill, Sanjeev Singh ; Ghori, Razi ; Kubiak, Peter ; Jin, Fan ; Norwood, Kevin Glen ; Chung, Hyun Cheol

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.94-94 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF V600E/K -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF V600E/K -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAF V600E/K -mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3

Ribas, Antoni ; Ferrucci, Pier Francesco ; Atkinson, Victoria ; Stephens, Rosalie ; Long, Georgina V. ; Lawrence, Donald P. ; Del Vecchio, Michele ; Hamid, Omid ; Schmidt, Henrik ; Schachter, Jacob ; Queirolo, Paola ; Miller, Wilson H. ; Carlino, Matteo S. ; Di Giacomo, Anna Maria ; Svane, Inge Marie ; Ghori, Razi ; Singh, Rohini ; Diede, Scott J. ; Ascierto, Paolo Antonio

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9516-9516 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort
Material Type:
Artigo 		Adicionar ao Meu Espaço

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort

Gomez-Roca, Carlos A. ; Yanez, Eduardo ; Im, Seock-Ah ; Castanon Alvarez, Eduardo ; Senellart, Hélène ; Doherty, Mark ; Garcia-Corbacho, Javier ; Lopez, Juanita Suzanne ; Basu, Bristi ; Maurice-Dror, Corinne ; Gill, Sanjeev Singh ; Ghori, Razi ; Kubiak, Peter ; Jin, Fan ; Norwood, Kevin Glen ; Chung, Hyun Cheol Cheol

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.3564-3564 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Data de Publicação 

De até
Refinar
  1. Antes de2017  (1)
  2. 2017Até2017  (1)
  3. 2018Até2018  (1)
  4. 2019Até2020  (4)
  5. Após 2020  (11)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.